Comparative perioperative outcomes of Hugo™ RAS versus laparoscopic and Da Vinci platforms for partial nephrectomy: a systematic review and meta-analysis.

In 30 seconds

This systematic review and meta-analysis compared Hugo™ RAS with da Vinci-assisted and laparoscopic partial nephrectomy. It included four observational cohort studies comprising 383 patients. No statistically significant differences were found across operative time, hospital stay, blood loss, postoperative creatinine, positive margins, postoperative adverse events, or trifecta attainment. For example, the odds ratio for trifecta attainment was 1.11 (95% CI [0.60, 2.07], p = 0.74). The findings provide preliminary evidence of comparable perioperative outcomes, but do not establish equivalence between platforms.

Key findings

• Operative time did not differ significantly: MD = 2.81 min, 95% CI [- 37.42, 43.03], p = 0.89.
• Trifecta attainment was similar between approaches: OR = 1.11, 95% CI [0.60, 2.07], p = 0.74.
• Overall postoperative adverse events showed no significant difference: OR = 1.05, 95% CI [0.39, 2.87], p = 0.92.
• The four observational cohorts included 383 subjects; no significant differences were reported for the other assessed perioperative outcomes.

Why it matters

Partial nephrectomy is a nephron-sparing option for localized T1 renal tumors, and surgical platforms may differ in cost and design. These pooled findings suggest that Hugo™ RAS has not shown worse measured perioperative outcomes than the compared minimally invasive approaches in the available studies. The evidence remains preliminary, so the results should be interpreted as an early comparison rather than proof of equivalent performance.

What to keep in mind

The synthesis included only four observational cohort studies, and the source describes the underlying evidence as preliminary, mostly single-centre and small-sample. The authors call for large multi-site randomized trials.